Start here if you're new
what it is
It makes devices and tissue products used in heart and blood vessel surgery.
how it gets paid
Last year Artivion made $441M in revenue. Aortic stents and stent grafts was the main engine at $176M, or 40% of sales.
why it's growing
Revenue grew 13.6% last year. Gross margin was 64.9%. That says the business still has pricing power.
what just happened
Revenue hit $325M, up 187% vs. prior year, while EPS reached $0.16.
At a glance
B+ balance sheet — decent shape, but not bulletproof
30/100 earnings predictability — expect surprises
148.4x trailing p/e — you're paying up for this one
1.0% return on capital — nothing to write home about
-$0.26 fy2024 eps est
xvary composite: 55/100 — below average
What they do
It makes devices and tissue products used in heart and blood vessel surgery.
You are not buying a gadget company. You are buying a surgeon workflow. Artivion sells into 100 countries, so its products sit inside a wide hospital network. Switching costs mean how hard it is to change suppliers, and that matters because a surgeon does not swap implant brands like phone cases.
How they make money
$441M
annual revenue · their business grew +13.6% last year
Aortic stents and stent grafts
$176M
Surgical sealants
$97M
On-X mechanical valves
$88M
Implantable tissues and patches
$80M
The products that matter
mature surgical franchise
aortic heart valve
core business · revenue split not shown here
This is the established side of the story, but the current snapshot does not show segment revenue or growth, so you cannot tell how much of the ~$2B valuation rests on this franchise versus the pipeline.
mature base
clinical pipeline catalyst
nexus triomphe ide trial
2026 watch · stock-moving event
This is where the market is leaning. A $43.03 stock against a visible $37 target tells you investors are already pricing in progress before the 2026 update arrives.
multiple driver
Key numbers
$441M
annual revenue
That is the size of the business in one year. You are not looking at a tiny lab company anymore.
64.9%
gross margin
That means Artivion keeps about 65 cents of every sales dollar before overhead. That is a healthy spread for a device maker.
16.2%
operating margin
This is the profit left after running the business. It shows the company converts sales into cash better than most small med-tech names.
$256M
long-term debt
That is the bill hanging over the business. Growth matters more when you owe this much.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 25 / 100
- long-term debt $256M (13% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for AORT right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Revenue hit $325M, up 187% vs. prior year, while EPS reached $0.16.
Gross margin was 64.9%. That says the business still has pricing power, even with a messy growth profile.
$325M
revenue
$0.16
eps
64.9%
gross margin
the number that mattered
The 187% revenue jump matters because it says the business is scaling fast from a much larger base than a year ago.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The risk picture starts with NEXUS TRIOMPHE timing and data, but that is not the only pressure point. AORT is a small-cap medical device stock already trading above the visible analyst target, with thin near-term earnings power and incomplete segment detail on this page.
med
the 2026 trial timeline slips
The stock is already leaning on the NEXUS TRIOMPHE IDE update arriving on time. Delay is not just a calendar issue here. It hits the part of the story investors are paying for.
Impact: a $43.03 stock against a visible $37 target leaves roughly 14.0% of downside to the street's shown view before you even debate the long-term upside.
med
the core business stays too opaque
This snapshot does not show segment revenue, segment growth, or segment margins for the established franchise. When proof is thin, narrative gets louder.
Impact: with price stability at 25 / 100, the stock can swing hard on interpretation because the current page does not give you enough operating detail to settle the argument.
med
a small earnings miss looks bigger than it is
Consensus EPS for the next quarter is just $0.04. That is a very small earnings base for a stock already priced with some confidence.
Impact: a one-cent miss changes the optics fast, while $256M of long-term debt and a risk rank of 3 mean the balance sheet is supportive, not magical.
this is a real grower, not a free lunch. the balance sheet is B+, but the 1.0% return on capital says every extra dollar still has to earn its keep.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next earnings report
Scheduled for April 30, 2026. The consensus EPS estimate is $0.04. For a stock with low price stability, that is enough to move shares before bigger pipeline news arrives.
timeline
NEXUS TRIOMPHE IDE data timing
Clinical updates are expected in 2026. If they land on time and read well, the market gets proof. If they slip, one of the main reasons investors are paying above the visible target gets weaker fast.
volatility
separate price action from business change
A 25 / 100 price stability score means the tape will probably overreact. Watch the catalyst path first. Watch the daily drama second.
valuation
the gap between price and target
The visible analyst target is $37 versus a $43.03 stock. Same period. Same starting point. Until the company delivers more proof, that gap is the market's confidence tax.
Analyst rankings
earnings predictability
30 / 100
earnings are harder to model here. in human-speak: expect surprises.
source: institutional data
Institutional activity
institutional ownership data for AORT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$43
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive